Xenon Pharmaceuticals (XENE) Receivables (2013 - 2025)
Xenon Pharmaceuticals (XENE) posted quarterly Receivables of $15.8 million for Q1 2025, up 1800.0% year-over-year from $833000.0 in Q1 2024, and up 685.07% quarter-over-quarter from $2.0 million in Q4 2024.
Xenon Pharmaceuticals (XENE) Receivables (2013 - 2025) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Receivables for 13 consecutive years, with $15.8 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Receivables rose 1800.0% year-over-year to $15.8 million; the TTM figure through Mar 2025 stood at $15.8 million (up 1800.0% YoY), while the FY2024 annual figure was $2.9 million, up 294.89% from the prior year.
- Receivables improved to $15.8 million in Q1 2025 per XENE's latest filing, from $2.0 million in the prior quarter.
- Across five years, Receivables topped out at $15.8 million in Q1 2025 and bottomed at $805000.0 in Q3 2023.
- Historically, Receivables has averaged $2.9 million across 5 years, with a median of $2.2 million in 2023.
- Annual changes were most pronounced in 2023 — Receivables plunged 67.57% — and 2025, when it jumped 1800.0%.
- Xenon Pharmaceuticals' Receivables stood at $2.8 million in 2021, then slumped by 64.34% to $986000.0 in 2022, then fell by 11.36% to $874000.0 in 2023, then surged by 130.66% to $2.0 million in 2024, then soared by 685.07% to $15.8 million in 2025.
- Business Quant data shows XENE's Receivables at $15.8 million in Q1 2025, $2.0 million in Q4 2024, and $1.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 15.83 Mn |
| Dec 31, 2024 | 2.02 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 853,000.00 |
| Mar 31, 2024 | 833,000.00 |
| Dec 31, 2023 | 874,000.00 |
| Sep 30, 2023 | 805,000.00 |
| Jun 30, 2023 | 2.12 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 986,000.00 |
| Sep 30, 2022 | 2.48 Mn |
| Jun 30, 2022 | 2.52 Mn |
| Mar 31, 2022 | 2.92 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Sep 30, 2021 | 3.24 Mn |
| Jun 30, 2021 | 2.92 Mn |
| Mar 31, 2021 | 5.06 Mn |
| Dec 31, 2020 | 1.82 Mn |
| Sep 30, 2020 | 1.61 Mn |
| Jun 30, 2020 | 1.79 Mn |